Bevacizumab prescribing practices for epithelial ovarian cancer in Australia

Nikki Burdett; Ganessan Kichenadasse

doi:10.1111/imj.14457

Bevacizumab prescribing practices for epithelial ovarian cancer in Australia

Nikki Burdett
, Ganessan Kichenadasse

Research output: Contribution to journal › Comment/debate

Abstract

Ovarian cancer represents a source of significant morbidity and mortality in developed countries. In 2018, it was the eighth most common cancer in females worldwide.1 While the age‐specific incidence has decreased, the absolute number of diagnoses has increased. In 2012, in Australia, there were 1384 new cases of ovarian cancer; in 2014 it was 1395...

Original language	English
Pages (from-to)	1334-1335
Number of pages	2
Journal	Internal Medicine Journal
Volume	49
Issue number	10
DOIs	https://doi.org/10.1111/imj.14457
Publication status	Published - 1 Oct 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bevacizumab
Ovarian cancer
patient outcomes
prescribing practices

Access to Document

10.1111/imj.14457Licence: In Copyright

Cite this

@article{c79e9ef4790a46459f7162537332bea9,

title = "Bevacizumab prescribing practices for epithelial ovarian cancer in Australia",

abstract = "Ovarian cancer represents a source of significant morbidity and mortality in developed countries. In 2018, it was the eighth most common cancer in females worldwide.1 While the age‐specific incidence has decreased, the absolute number of diagnoses has increased. In 2012, in Australia, there were 1384 new cases of ovarian cancer; in 2014 it was 1395...",

keywords = "Bevacizumab, Ovarian cancer, patient outcomes, prescribing practices",

author = "Nikki Burdett and Ganessan Kichenadasse",

year = "2019",

month = oct,

day = "1",

doi = "10.1111/imj.14457",

language = "English",

volume = "49",

pages = "1334--1335",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley \& Sons, Inc",

number = "10",

}

TY - JOUR

T1 - Bevacizumab prescribing practices for epithelial ovarian cancer in Australia

AU - Burdett, Nikki

AU - Kichenadasse, Ganessan

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Ovarian cancer represents a source of significant morbidity and mortality in developed countries. In 2018, it was the eighth most common cancer in females worldwide.1 While the age‐specific incidence has decreased, the absolute number of diagnoses has increased. In 2012, in Australia, there were 1384 new cases of ovarian cancer; in 2014 it was 1395...

AB - Ovarian cancer represents a source of significant morbidity and mortality in developed countries. In 2018, it was the eighth most common cancer in females worldwide.1 While the age‐specific incidence has decreased, the absolute number of diagnoses has increased. In 2012, in Australia, there were 1384 new cases of ovarian cancer; in 2014 it was 1395...

KW - Bevacizumab

KW - Ovarian cancer

KW - patient outcomes

KW - prescribing practices

UR - https://www.scopus.com/pages/publications/85073107593

U2 - 10.1111/imj.14457

DO - 10.1111/imj.14457

M3 - Comment/debate

C2 - 31602777

AN - SCOPUS:85073107593

SN - 1444-0903

VL - 49

SP - 1334

EP - 1335

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 10

ER -

Bevacizumab prescribing practices for epithelial ovarian cancer in Australia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this